Home Healthcare Medical Devices Biodegradable Stents Market

Biodegradable Stents Market Size, Share & Trends Analysis Report By Product (Polymer Based, Biodegradable Stents, Metal Based Biodegradable Stents), By Applications (Coronary Arteary Disease, Peripheral Artery Disease), By Absorption Rate (Slow Absorption Rate, Intermediate Absorption Rate, Fast Absorption Rate), By End-User (Hospital, Cardiac Centers) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: November 19, 2026 | Author: Debashree Bora | Report Code: SR10DR

Biodegradable Stents Market Size & Growth Analysis

The global biodegradable stents market size was valued at USD 442.17 million in 2025 and is projected to grow from USD 476.62 million in 2026 to USD 868.55 million by 2034, registering a CAGR of 7.79% during the forecast period from 2026 to 2034. North America dominated the biodegradable stents market with a share of 38.6% in 2025.

Biodegradable stents are temporary medical implants used to keep blocked or narrowed blood vessels open and gradually dissolve after the vessel has healed. These stents are typically made from bioresorbable polymers or biodegradable metal alloys that provide structural support during recovery and then naturally break down within the body over time. By eliminating the need for a permanent implant, biodegradable stents help reduce long-term complications associated with traditional metal stents and support the restoration of normal vascular function.

Biodegradable Stents Market Key Takeaways

Global Market Size & Growth

2025 Market Size
USD 442.17 Million
2026 Market Size
USD 476.62 Million
2034 Projected Market Size
USD 868.55 Million
Forecast Period
2026–2034
Base Year
2025
Market CAGR (2026–2034)
7.79%

Regional Insights

Largest Regional Market (2025)
North America
North America Market Share (2025)
38.6%
Fastest-growing Region
Europe
Europe CAGR (2026–2034)
9.35%

Segment Insights

By Product
Leading Segment
Polymer Based
Market Share in 2025 58.4%
By Application
Fastest-growing Segment
Coronary Artery Disease
CAGR 8.55% (2026–2034)
By Absorption Rate
Leading Segment
Intermediate Absorption Rate
Market Share in 2025 46.2%
By End User
Fastest-growing Segment
Cardiac Centers
CAGR 8.7% (2026–2034)
Biodegradable Stents Market Size , Share and Growth Forecast 2026-2034

Download a Free SampleTo learn more about this report.

Biodegradable Stents Market Dynamics

01

Need to Reduce Long-Term Implant Complications Supports Biodegradable Stents Market Demand

Concerns about long-term complications associated with permanent metallic implants, including chronic vessel irritation and difficulties during future cardiovascular interventions, support clinical interest in biodegradable stents. These devices provide temporary vascular support and gradually break down after the treated artery recovers. For example, bioresorbable vascular scaffolds offer an alternative approach for selected patients undergoing coronary angioplasty. The need for temporary implants supports demand for biodegradable stents among cardiologists and healthcare providers.

02

Specialized Medical Device Manufacturing Strengthens Biodegradable Stents Market Supply

Advances in precision manufacturing, polymer processing, and medical device fabrication help manufacturers produce biodegradable stents with controlled structural properties and degradation profiles. Specialized production techniques support consistent stent dimensions, mechanical strength, and material quality. For example, manufacturers use precision laser cutting and polymer processing to develop bioresorbable vascular scaffolds for coronary applications.

03

Impact Analysis of Key Drivers in Biodegradable Stents Market

DriversMarket Impact

High Cost of Biodegradable Stent Development and Production

High research, material development, clinical testing, and manufacturing costs increase the final price of biodegradable stents. These expenses limit affordability for healthcare providers and restrict adoption in cost-sensitive healthcare markets.

Limited Long-Term Clinical Evidence

The limited availability of long-term clinical data on safety, effectiveness, and vessel healing creates uncertainty among cardiologists. This can slow clinical acceptance and delay the wider adoption of biodegradable stents compared with established metallic stents.

Risk of Scaffold Thrombosis and Mechanical Failure

Complications such as scaffold thrombosis, inadequate radial strength, and premature structural breakdown create concerns about patient safety. These risks can limit physician confidence and restrict the use of biodegradable stents in certain cardiovascular procedures.

Complexity of Biodegradation and Absorption Control

The need to maintain sufficient mechanical support while ensuring predictable material degradation creates technical challenges for manufacturers. Variations in degradation rates can affect vessel healing and increase product development difficulties.

Stringent Regulatory Approval Requirements

Extensive clinical trials, safety assessments, and regulatory validation increase the time and cost required to commercialize biodegradable stents. These requirements can delay product launches and restrict market entry for smaller medical device manufacturers.

Competition from Established Drug-Eluting Metallic Stents

Widely adopted drug-eluting metallic stents offer established clinical performance, physician familiarity, and broad hospital availability. Their strong market presence creates competitive pressure and limits the transition toward biodegradable alternatives.

Limited Availability of Specialized Treatment Expertise

The use of biodegradable stents requires appropriate procedural knowledge and familiarity with device-specific characteristics. Limited physician training and experience across some healthcare facilities can restrict adoption and slow market penetration.

01

Risk of Stent Thrombosis and Restenosis Limits Clinical Adoption

The risk of stent thrombosis and restenosis creates concerns about the long-term safety and performance of biodegradable stents. Scaffold degradation, delayed vessel healing, and changes in mechanical support can increase the possibility of complications and repeat interventions. These risks can reduce physician confidence and encourage preference for conventional drug-eluting stents, limiting the adoption of biodegradable alternatives.

02

Complex Implantation Procedures Restrict Wider Clinical Use

The implantation of biodegradable stents requires precise vessel sizing, proper lesion preparation, and controlled device deployment to achieve reliable clinical outcomes. These procedural requirements increase treatment complexity and create a greater need for specialized equipment and experienced interventional cardiologists. Limited access to trained professionals and advanced cardiac facilities can discourage adoption and slow market expansion.

03

Impact Analysis of Key Restraints in Biodegradable Stents Market

RestraintsMarket Impact

Risk of Stent Thrombosis and Restenosis

Concerns about stent thrombosis, restenosis, and delayed vessel healing can reduce physician confidence in biodegradable stents. These risks may encourage healthcare providers to prefer conventional drug-eluting stents with established clinical performance, limiting the adoption of biodegradable alternatives.

Complex Implantation Procedures

The need for precise vessel sizing, proper lesion preparation, and controlled device deployment increases procedural complexity. Dependence on specialized equipment and experienced interventional cardiologists can restrict adoption in hospitals with limited infrastructure and technical expertise.

Limited Long-Term Clinical Evidence

Insufficient long-term clinical data on degradation behavior, vessel healing, and treatment outcomes can create uncertainty among physicians and healthcare providers. This uncertainty may delay clinical acceptance and limit the routine use of biodegradable stents.

High Development and Manufacturing Costs

Advanced biomaterials, specialized manufacturing processes, and extensive clinical testing increase product development expenses. Higher production costs can raise device prices and restrict adoption among hospitals with limited healthcare budgets.

Competition from Conventional Drug-Eluting Stents

Established clinical performance, wider availability, and physician familiarity with conventional drug-eluting stents create strong competition. This preference can make it difficult for biodegradable stent manufacturers to gain market share and establish broader clinical adoption.

Stringent Regulatory Approval Requirements

Strict requirements for biocompatibility, mechanical performance, degradation characteristics, and clinical safety increase approval timelines and compliance costs. These requirements can delay product commercialization and create entry barriers for smaller medical device manufacturers.

01

Strategic Collaborations for Clinical Research and Commercialization

Biodegradable stent manufacturers, biotechnology companies, cardiovascular device developers, and research institutions can collaborate on clinical trials, product validation, and regulatory approvals. These partnerships can create revenue opportunities through technology licensing, co-development agreements, research partnerships, and commercialization deals.

02

Development of Specialized Stents for Complex Vascular Conditions Opens New Market Opportunities

Cardiovascular device manufacturers, interventional cardiology companies, and medical technology developers can explore specialized biodegradable stents for complex conditions such as bifurcation lesions and small-vessel disease. Investments in application-specific designs and clinical validation can create revenue opportunities through premium product offerings, hospital procurement contracts, and partnerships with specialty cardiac centers. Companies such as Abbott Laboratories and REVA Medical can benefit from expanding their cardiovascular device portfolios to address specialized treatment requirements.

Biodegradable Stents Market Segmentation Analysis

By Product

The polymer based segment accounted for the largest market share of 58.4%,supported by the flexibility, biocompatibility, and controlled degradation properties of polymer materials. These characteristics make them suitable for developing stents that provide temporary support before gradually dissolving in the body.

The biodegradable stents segment is projected to grow at a CAGR of 8.25% during the forecast period, driven by demand for temporary vascular support devices that reduce the need for permanent implants. Their potential to minimize long-term complications associated with permanent metallic stents supports research and clinical adoption.

Biodegradable Stents Market Size By Segments

Request Customizationto receive a tailored report.

By Applications

The coronary artery disease segment is projected to grow at a CAGR of 8.55% during the forecast period, driven by demand for minimally invasive treatments that restore blood flow in narrowed or blocked coronary arteries. The adoption of advanced stent technologies supports treatment options for patients with coronary artery disease.

The peripheral artery disease segment is projected to grow at a CAGR of 8.2% during the forecast period, supported by demand for minimally invasive procedures to treat narrowed arteries outside the heart. Biodegradable stents offer potential benefits through temporary vessel support without leaving a permanent implant.

By Absorption Rate

The intermediate absorption rate segment accounted for the largest market share of 46.2%, supported by its potential to balance the required period of vessel support with gradual material degradation. This absorption profile helps maintain structural support during vascular healing while allowing the stent to dissolve over time.

The fast absorption rate segment is projected to grow at a CAGR of 8.35% during the forecast period, driven by interest in stents that provide temporary support and degrade within shorter periods. Advances in biodegradable materials and polymer engineering support the development of devices with controlled absorption profiles.

By End User

The hospital segment is projected to grow at a CAGR of 8.35% during the forecast period, driven by the availability of specialized cardiac departments, catheterization laboratories, and trained interventional cardiologists. Hospitals also manage a large volume of complex cardiovascular procedures.

The cardiac centers segment is projected to grow at a CAGR of 8.7% during the forecast period, supported by the expansion of specialized cardiovascular care and demand for minimally invasive cardiac procedures. Dedicated facilities also improve access to advanced stent technologies and focused patient care.

Biodegradable Stents Market Share By Segments

Speak to an Analystto discuss market opportunities.

Biodegradable Stents Market Regional Outlook

North America Biodegradable Stents Market

The North America biodegradable stents market accounted for the largest regional share of 38.6% in 2025.

U.S. Biodegradable Stents Market

U.S. companies such as Abbott Laboratories, Elixir Medical Corporation, REVA Medical, and Amaranth Medical are involved in the development of bioresorbable vascular scaffolds and biodegradable stent technologies. Their work focuses on polymer-based and absorbable materials for coronary and peripheral vascular applications.

Canada Biodegradable Stents Market

Companies with Canadian operations, such as Abbott Laboratories, Boston Scientific, Medtronic, and Biotronik, contribute to the country's cardiovascular device and stent technology ecosystem. Their activities in stent development, bioabsorbable scaffold technologies, and clinical research support the development of advanced vascular treatment solutions.

North America Biodegradable Stents Market Revenue Share 2025

Unlock Regional Insightsto access country-level data, & regional trends.

Europe Biodegradable Stents Market

The Europe biodegradable stents market is expected to register a CAGR of 6.7% during the forecast period, making it the fastest-growing regional market.

U.K. Biodegradable Stents Market

UK-based Arterius Limited is developing its ArterioSorb bioresorbable scaffold for peripheral arterial disease, designed to support the vessel for 3–6 months before being fully absorbed by the body. The company’s polymer-based technology and drug delivery platform reflect the UK's role in developing next-generation biodegradable vascular devices.

Germany Biodegradable Stents Market

Germany-based BIOTRONIK SE & Co. KG is advancing magnesium-based bioresorbable scaffold technology for vascular interventions, with research focused on vessel restoration and temporary mechanical support. Its development activities strengthen Germany's position in the biodegradable stents market and support innovation in absorbable cardiovascular implants.

Asia Pacific Biodegradable Stents Market

The Asia Pacific biodegradable stents market is expected to register a CAGR of 6.2% during the forecast period.

Japan Biodegradable Stents Market

Japanese companies such as Kaneka Corporation and Kyoto Medical Planning Co., Ltd. are involved in biodegradable stent development. Kaneka acquired Japan Medical Device Technology (JMDT), a developer of bioresorbable coronary stents, while Kyoto Medical Planning has developed the IGAKI-TAMAI bioresorbable coronary stent and the REMEDY biodegradable peripheral stent.

China Biodegradable Stents Market

Chinese companies such as MicroPort Scientific Corporation, Lepu Medical Technology, and Shandong Hua'an Biotechnology are active in biodegradable stent development. MicroPort received NMPA approval for its Firesorb bioresorbable coronary scaffold, while Lepu develops the NeoVas bioresorbable scaffold and Hua'an focuses on biodegradable cardiovascular stent technologies.

India Biodegradable Stents Market

Indian companies such as Meril Life Sciences and S3V Vascular Technologies are involved in the development of bioresorbable vascular scaffold technologies. Meril's MeRes100 is a biodegradable polymer-based coronary scaffold, while S3V Vascular Technologies is associated with the development of its VIVO ISAR bioresorbable stent platform.

Competitive Landscape

The biodegradable stents market competitive landscape is moderately fragmented, with a mix of medical device manufacturers, cardiovascular technology developers, and specialized bioresorbable implant companies. Key players such as Abbott Laboratories, Biotronik, and REVA Medical are estimated to account for approximately 20–25% of the biodegradable stents market share.

Established players compete primarily on product innovation, clinical performance, regulatory approvals, and global distribution networks. Emerging and specialized players in the biodegradable stents market ecosystem compete through advanced biodegradable materials, specialized stent designs, clinical research, and cost-effective technologies.

List of Key and Emerging Players in Biodegradable Stents Market

Abbott Laboratories (U.S.)
Biotronik (Germany)
REVA Medical (U.S.)
Elixir Medical Corporation (U.S.)
Kyoto Medical Planning Co., Ltd. (Japan)
Arterius Limited (U.K.)
OrbusNeich Medical (Hong Kong, China)

Key Industry Developments

June 2026 – Elixir Medical Reports Positive Long-Term Outcomes for DynamX Bioadaptor System
Elixir Medical Corporation announced positive long-term clinical data for its DynamX Coronary Bioadaptor System, demonstrating sustained vessel function restoration and favorable patient outcomes. The company continued expanding physician adoption and commercial availability across international markets. (Official company announcement)
April 2026 – REVA Medical Advances Fantom Bioresorbable Scaffold Development Program
REVA Medical, Inc. continued advancing development of its next-generation Fantom bioresorbable scaffold, focusing on enhanced radial strength, visibility during implantation, and long-term vessel healing to support future commercialization initiatives. (Official company update)
February 2026 – Kyoto Medical Planning Expands Clinical Evaluation of Bioresorbable Coronary Stent Technologies
Kyoto Medical Planning Co., Ltd. expanded clinical evaluation programs for its bioresorbable coronary stent platform, supporting next-generation treatment options for coronary artery disease with improved vascular restoration capabilities. (Clinical development update)
November 2025 – Elixir Medical Expands International Commercialization of DynamX Coronary Bioadaptor
Elixir Medical accelerated commercial expansion of its DynamX coronary bioadaptor system across additional international markets following increased physician adoption and continued positive clinical evidence supporting treatment of coronary artery disease. (Official company announcement)

Report Scope

Segmentation

By Product 3
  • Polymer Based
  • Biodegradable Stents
  • Metal Based Biodegradable Stents
By Applications 2
  • Coronary Arteary Disease
  • Peripheral Artery Disease
By Absorption Rate 3
  • Slow Absorption Rate
  • Intermediate Absorption Rate
  • Fast Absorption Rate
By End-User 2
  • Hospital
  • Cardiac Centers

Geographies Covered

North America 2
  • U.S.
  • Canada
Europe 8
  • U.K.
  • Germany
  • France
  • Spain
  • Italy
  • Russia
  • Nordic
  • Benelux
APAC 8
  • China
  • Korea
  • Japan
  • India
  • Australia
  • Singapore
  • Taiwan
  • South East Asia
Middle East and Africa 6
  • UAE
  • Turkey
  • Saudi Arabia
  • South Africa
  • Egypt
  • Nigeria
LATAM 5
  • Brazil
  • Mexico
  • Argentina
  • Chile
  • Colombia
Competitive Coverage Abbott Laboratories (U.S.) · Biotronik (Germany) · REVA Medical (U.S.) · Elixir Medical Corporation (U.S.) · Kyoto Medical Planning Co., Ltd. (Japan)
Research Deliverables Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends

Customize This Reportto Match Your Strategic Objectives

Frequently Asked Questions (FAQs)

The biodegradable stents market size is valued at USD 476.62 Million in 2026 and is projected to reach USD 868.55 Million by 2034, at a CAGR of 7.79% during the forecast period 2026-2034.
North America dominated the market with a share of 38.6% in 2025.
The leading players in this market are Abbott Laboratories, Biotronik, Reva Medical, Elixir Medical Corporation, Kyoto Medical Planning Co. Ltd..
The biodegradable stents market is projected to grow at a CAGR of 7.79% during the forecast period of 2026 2034.
About the Author
Debashree Bora
Debashree Bora
Healthcare Lead

Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, and competitive dynamics.
Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.

Report Details
−
Trusted by Industry Leaders
LG ElectronicsAMCAD EngineeringKOBE STEEL LTD.Hindustan National Glass & Industries LimitedVoith GroupInternational PaperHansol PaperWhirlpool CorporationSonySamsung ElectronicsQualcommGoogleFiservVeto-PharmaNippon Becton DickinsonMerckArgon Medical DevicesAbbottAjinomotoDenonDoosanMeiji Seika Kaisha LtdLG ChemicalsLCY chemical groupBayerAirraneBASFToyota IndustriesNissan MotorsNeenahMitsubishiHyundai Motor CompanyHondaCRP Industries IncpewagLGEPanasonicLubrizol CorporationLeonardoJohnson & JohnsonHB FullerMITSUBISHI CHEMICALHyundai MobisAmazon
Request SampleOrder Report Now